Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients
- Wall Street ends mixed after punishing week
- '3600 is the New Bull Case': Outflows from Energy and Materials Highest in Several Years - BofA
- Dollar catches a break after bruising week as investors turn risk averse
- Apple (AAPL) is a 'Compelling Name To Own' Right Now, iPhone Sales Trending Ahead of Guidance - Wedbush's Ives
- Deere (DE) Falls on Sales Miss, JPMorgan Sees 'Aggressive' Guidance and Downside Risk
A retrospective analysis of Novocure’s (Nasdaq: NVCR) Tumor Treating Fields (TTFields) therapy shows that TTFields therapy is safe in adult glioblastoma patients with implanted non-programmable shunts. The data were presented on Nov. 20 at the 20th Annual Society for Neuro-Oncology Meeting in San Antonio.
The analysis included 1,402 recurrent glioblastoma patients in the U.S. who were treated with TTFields therapy between November 2011 and May 2015. Among those patients, 49 had implanted medical devices: 44 patients had non-programmable shunts, two patients had programmable shunts and three patients had pacemakers/defibrillators. Shunts are implanted in the brain to resolve hydrocephalus, a condition characterized by a build-up of fluid within the ventricles of the brain that occurs in 2.5 percent to 10 percent of GBM patients. Safety data were analyzed to detect adverse events related to the implanted medical devices.
Adverse events reported by the 49 patients with implanted medical devices did not raise any new safety concerns regarding the use of TTFields therapy, and the analysis indicates that TTFields therapy is safe in patients with non-programmable shunts. Further investigation is needed to conclude whether TTFields therapy is safe in patients with programmable shunts and in patients with pacemakers/defibrillators.
After reviewing the safety data available from newly diagnosed GBM patients with shunts in Novocure’s EF-14 trial, the U.S. Food and Drug Administration removed a pre-existing contraindication in October 2015 stating that Optune should not be used in patients with non-programmable shunts.
“The removal of the contraindication from its regulatory labeling increases Optune’s addressable GBM patient population by approximately 5 percent,” said Asaf Danziger, Novocure’s Chief Executive Officer. “Novocure strives to ensure the safety and efficacy of TTFields in all patients. This research supports that mission, while making our therapy available to a growing number of patients who suffer from this aggressive form of brain cancer.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walker & Dunlop (WD) Outlines Plans for Continued Growth, Intents to Grow Revenues to $2B by 2025
- AbbVie (ABBV) Submits NDA to U.S. FDA for Investigational ABBV-951 for the Treatment of Advanced Parkinson's Disease
- Regeneron (REGN), Sanofi (SNY) Confirm FDA Approves Dupixent as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!